| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4302 | 2013 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2225 | 2015 |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous … M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ... The Lancet Oncology 17 (4), 425-439, 2016 | 1737 | 2016 |
| Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial V Galimberti, BF Cole, S Zurrida, G Viale, A Luini, P Veronesi, P Baratella, ... The lancet oncology 14 (4), 297-305, 2013 | 1281 | 2013 |
| Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 386 (10001), 1341-1352, 2015 | 1275 | 2015 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1237 | 2017 |
| Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 AS Coates, A Keshaviah, B Thürlimann, H Mouridsen, L Mauriac, ... Journal of clinical oncology 25 (5), 486-492, 2007 | 1149 | 2007 |
| Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen M Dowsett, J Cuzick, J Ingle, A Coates, J Forbes, J Bliss, M Buyse, ... Journal of Clinical Oncology 28 (3), 509-518, 2010 | 1039 | 2010 |
| Overall survival with palbociclib and fulvestrant in advanced breast cancer NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ... New England journal of medicine 379 (20), 1926-1936, 2018 | 1034 | 2018 |
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial D Tripathy, SA Im, M Colleoni, F Franke, A Bardia, N Harbeck, SA Hurvitz, ... The lancet oncology 19 (7), 904-915, 2018 | 891 | 2018 |
| Overall survival with ribociclib plus endocrine therapy in breast cancer SA Im, YS Lu, A Bardia, N Harbeck, M Colleoni, F Franke, L Chow, J Sohn, ... New England journal of medicine 381 (4), 307-316, 2019 | 889 | 2019 |
| Adjuvant exemestane with ovarian suppression in premenopausal breast cancer O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, ... New England Journal of Medicine 371 (2), 107-118, 2014 | 870 | 2014 |
| Adjuvant ovarian suppression in premenopausal breast cancer PA Francis, MM Regan, GF Fleming, I Láng, E Ciruelos, M Bellet, ... New England Journal of Medicine 372 (5), 436-446, 2015 | 846 | 2015 |
| Tailoring adjuvant endocrine therapy for premenopausal breast cancer PA Francis, O Pagani, GF Fleming, BA Walley, M Colleoni, I Láng, ... New England Journal of Medicine 379 (2), 122-137, 2018 | 615 | 2018 |
| Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V M Colleoni, Z Sun, KN Price, P Karlsson, JF Forbes, B Thürlimann, ... Journal of clinical oncology 34 (9), 927, 2016 | 599 | 2016 |
| Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 HJ Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, ... Annals of Oncology 30 (10), 1541-1557, 2019 | 596 | 2019 |
| Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels M Colleoni, A Rocca, MT Sandri, L Zorzino, G Masci, F Nole, G Peruzzotti, ... Annals of Oncology 13 (1), 73-80, 2002 | 579 | 2002 |
| Very young women (< 35 years) with operable breast cancer: features of disease at presentation M Colleoni, N Rotmensz, C Robertson, L Orlando, G Viale, G Renne, ... Annals of Oncology 13 (2), 273-279, 2002 | 539 | 2002 |
| Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents Y Shaked, E Henke, JML Roodhart, P Mancuso, MHG Langenberg, ... Cancer cell 14 (3), 263-273, 2008 | 526 | 2008 |
| International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? O Pagani, E Senkus, W Wood, M Colleoni, T Cufer, S Kyriakides, A Costa, ... Journal of the National Cancer Institute 102 (7), 456-463, 2010 | 498 | 2010 |
